← board
LFCR
distress 1/10 · well-funded / low risk$4.55-1%today-48% from 52w high
Revenue
pre-revenue
Liquidity
$21M
Runway
—
Shares 1y
+0%
Price & events
-47.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-8.1%
1W
-19.6%
1M
-7.5%
3M
-47.0%
6M
-39.6%
1Y
-19.0%
2Y
-61.5%
5Y
-59.0%
All
Overview
- Market Cap
- $170.71M
- Enterprise Value
- $298.66M
- Volume
- 3.07K
- 52 Week Range
- $3.66 – $8.82
- Total Shares
- 37.51M
- Float Shares
- 19.43M
- Short %
- 7.82%
- % Held by Insiders
- 2.83%
- % Held by Institutions
- 77.24%
- RVOL
- 0.02x
- Beta
- 1.06
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $7 (+50% upside) · 3 analysts
- 2026-06-16Barrington ResearchOutperform
- 2026-04-29Barrington ResearchOutperform
- 2026-03-27Barrington ResearchOutperform
- 2026-03-24Barrington ResearchOutperform
- 2026-03-17Barrington ResearchMarket Perform → Outperform
- 2025-09-04KeybancSector Weight
Competitors
- none identified
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.